The knockdown efficiency of GP and GA ranged from approximately 30% to 70% in different patient cell lines (Figure 3B), confirming the effectiveness of the CRISPR/Cas13d system in suppressing RAN translation in C9orf72 repeat–associated ALS patient cells. Here, RAN is linked to amyotrophic lateral sclerosis.